<DOC>
	<DOCNO>NCT01559974</DOCNO>
	<brief_summary>The purpose study determine whether intake Vitamin D positive effect walk ability patient peripheral artery occlusive disease . Skeletal muscle fiber change morphology peripheral artery occlusive disease . In patient Vitamin D-deficiency also change skeletal muscle fiber . The investigator hypothesis patient peripheral artery occlusive disease subsequent change muscle fiber morphology calf muscle might take profit administration Vitamin D combination training .</brief_summary>
	<brief_title>Vitamin D Walking Ability Patients With Peripheral Artery Occlusive Disease</brief_title>
	<detailed_description>Background On one hand , patient suffer peripheral artery occlusive disease may significant decrease walk ability . When insufficient supply oxygen muscle , especially calf muscle , structural change skeletal muscle fiber appear . On hand , patient might also insufficient supply Vitamin D often case general population . A deficiency Vitamin D also cause structural change skeletal muscle cause muscle weakness . Hypothesis Vitamin D - intake improve walk ability patient peripheral artery occlusive disease eventually Vitamin D - deficiency . Aim study To evaluate influence Vitamin D - intake walk ability patient peripheral artery occlusive disease , would simple , safe non-invasive measure positive effect quality life indirectly cardiovascular health general ( good mobility ) . Primary endpoint : Measurement walk ability treadmill test begin 3 month-treatment Vitamin D , combination home-based training . Secondary endpoint : - Measurement calf muscle perfusion indirect parameter walk ability , measurement beginning , three month 6 month follow . - Quality life questionnaire ( SF 36 walk impairment questionnaire ) , visual analogue scale . Study design : Prospective , randomised , double-blind , placebo-controlled , investigator-initiated pilot study study duration 3 month 3 month - follow . Study course : 6 study visit plan . - Visit 0 : screening visit , lab ( Calcium , Vitamin D3 ) , questionnaires - Visit 1 : treadmill test , measurement calf muscle perfusion , intake first monthly dose Cholecalciferol 45'000 unit ( placebo ) - Visit 2 ( 1 month ) : vital parameter , second dose 45'000 unit Cholecalciferol ( placebo ) - Visit 3 ( 2 month ) : vital parameter , third dose 45'000 unit Cholecalciferol ( placebo ) - Visit 4 ( 3 month ) : treadmill test , measurement calf muscle perfusion , lab ( Calcium , Vitamin D3 ) , questionnaires - Visit 5 ( 6 month ) : treadmill test , measurement calf muscle perfusion , lab ( Calcium , Vitamin D3 ) , questionnaire</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>peripheral artery obliterative disease Rutherford 1 3 informed consent motivation inability treadmill walk motivate female patient : childbearing age ( age limit 49 year ) PTA surgical revascularisation within 3 month study entry cancer , life expectancy low 6 month ongoing therapy Vitamin D 25OHVitamin D level 125 nmol/l contraindication Vitamin D intake ( sarcoidosis , acute lung tbc , hypercalcemia , intake Vitamin D analogs contraindication ultrasound contrast agent ( know hypersensitivity , recent acute coronary syndrome , unstable ischemic heart disease , PTCA , heart insufficiency NYHA III IV , severe rhythm disorder , know right left shunt , severe pulmonary artery hypertension , adult respiratory distress syndrome</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Peripheral arterial disease</keyword>
	<keyword>PAOD</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>Walking impairment</keyword>
</DOC>